These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12621311)

  • 41. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A-71623, a selective CCK-A receptor agonist, suppresses food intake in the mouse, dog, and monkey.
    Asin KE; Bednarz L; Nikkel AL; Gore PA; Nadzan AM
    Pharmacol Biochem Behav; 1992 Aug; 42(4):699-704. PubMed ID: 1513850
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls.
    Koszycki D; Torres S; Swain JE; Bradwejn J
    Psychosom Med; 2005; 67(4):590-5. PubMed ID: 16046372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neurobiological investigations into the role of cholecystokinin in panic disorder.
    Bradwejn J
    J Psychiatry Neurosci; 1993 Jul; 18(4):178-88. PubMed ID: 8104032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of cerebral neurogenic vasodilation by L-glutamine and nitric oxide synthase inhibitors and its reversal by L-citrulline.
    Lee TJ; Sarwinski S; Ishine T; Lai CC; Chen FY
    J Pharmacol Exp Ther; 1996 Feb; 276(2):353-8. PubMed ID: 8632296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cholecystokinin secretagogue-induced gastroprotection: role of nitric oxide and blood flow.
    West SD; Helmer KS; Chang LK; Cui Y; Greeley GH; Mercer DW
    Am J Physiol Gastrointest Liver Physiol; 2003 Mar; 284(3):G399-410. PubMed ID: 12444009
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selective activation of CCK-B receptors does not induce sleep and does not affect EEG slow-wave activity and brain temperature in rats.
    Chang HY; Kapás L
    Physiol Behav; 1997 Jul; 62(1):175-9. PubMed ID: 9226359
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reversed behavioral effect of cholecystokinin after frontal decortication in rats.
    Itoh S; Katsuura G; Itoh T; Morimoto T
    Life Sci; 1994; 55(11):PL213-6. PubMed ID: 8072383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cholecystokinin receptors regulate sperm protein tyrosine phosphorylation via uptake of HCO3-.
    Zhou Y; Ru Y; Shi H; Wang Y; Wu B; Upur H; Zhang Y
    Reproduction; 2015 Oct; 150(4):257-68. PubMed ID: 26175429
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cholecystokinin and Panic Disorder: Reflections on the History and Some Unsolved Questions.
    Rehfeld JF
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577128
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The cholecystokinin hypothesis of anxiety and panic disorder.
    Bradwejn J; Koszycki D
    Ann N Y Acad Sci; 1994 Mar; 713():273-82. PubMed ID: 8185169
    [No Abstract]   [Full Text] [Related]  

  • 53. Investigation of cholecystokinin system genes in panic disorder.
    Kennedy JL; Bradwejn J; Koszycki D; King N; Crowe R; Vincent J; Fourie O
    Mol Psychiatry; 1999 May; 4(3):284-5. PubMed ID: 10395221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sympathetic modulation of nitrergic neurogenic vasodilation in cerebral arteries.
    Lee TJ
    Jpn J Pharmacol; 2002 Jan; 88(1):26-31. PubMed ID: 11859855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms.
    Le Mellédo JM; Bradwejn J; Koszycki D; Bichet DG; Bellavance F
    Biol Psychiatry; 1998 Sep; 44(5):364-6. PubMed ID: 9755359
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ventilatory response to cholecystokinin tetrapeptide in anaesthetized dogs.
    Bates JH; Bradwejn J
    Neuroreport; 1995 Dec; 6(18):2513-7. PubMed ID: 8741752
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Some cholecystokinin-8 immunoreactive fibers in large pial arteries originate from trigeminal ganglion.
    Liu-Chen LY; Norregaard TV; Moskowitz MA
    Brain Res; 1985 Dec; 359(1-2):166-76. PubMed ID: 3907751
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuropeptides and anxiety: focus on cholecystokinin.
    Lydiard RB
    Clin Chem; 1994 Feb; 40(2):315-8. PubMed ID: 8313613
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of endothelium in the responses of human intracranial arteries to a slight reduction of extracellular magnesium.
    Szabó C; Hardebo JE; Salford LG
    Exp Physiol; 1992 Jan; 77(1):209-11. PubMed ID: 1543585
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.
    de Montigny C
    Arch Gen Psychiatry; 1989 Jun; 46(6):511-7. PubMed ID: 2730276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.